Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide alternative dosing PK/PD bioequivalence pilot study
2021-006646-12Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pomalidomide in multiple myeloma (MM) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: AUC/MIC ratio and Ctrough relative to EC50. Started Aug 2022; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-006646-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006646-12.